ArticleThe Journal of experimental medicine2019
Endothelial ERK1/2 signaling maintains integrity of the quiescent endothelium.
Abstract read
In one paragraph
Article in The Journal of experimental medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 70 citations in OpenAlex.
- Lung Pericytes: Molecular Mechanisms, Signaling Pathways, and Roles in Pulmonary Diseases.Comprehensive Physiology · 2026Review
- MMP8 exacerbates sepsis-induced pulmonary vascular leakage by disruption of endothelial VE-cadherin through ERK signalling.Molecular biomedicine · 2026Article
- Apelin-APLNR pathway across development, inflammation, and vascular remodeling: an endothelial perspective.Experimental & molecular medicine · 2026Review
- Decoding the antihypertensive mechanism of cannabidiol through integrative bioinformatics and machine learning.Journal of cannabis research · 2026Article
- Trametinib Decreased Intracerebral Hemorrhages and Endothelial-to-Mesenchymal Transition in KRASStroke · 2026Article
- NF-κB signaling as a critical inflammatory node in pulmonary arterial hypertension: from vascular remodeling to right heart failure.Frontiers in immunology · 2026Review
- Key RNA-binding proteins in renal fibrosis: a comprehensive bioinformatics and machine learning framework for diagnostic and therapeutic insights.Renal failure · 2025Article
- BRAF inhibition increases TGFβ2 production and stimulates metastasis in mice with endogenous BRAFProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Heparanase 2 Modulates Vascular Permeability via Heparan Sulfate-Dependent Growth Factor Signaling.Arteriosclerosis, thrombosis, and vascular biology · 2025Article
- CYB5R4 sustains endothelial proliferation and ischemia-induced angiogenesis by maintaining RRM2-dependent nucleotide balance.bioRxiv : the preprint server for biology · 2025Article
- A mechanistic computational model of HGF-VEGF-mediated endothelial cell proliferation and vascular permeability.iScience · 2025Article
- Human endothelial colony forming cells (ECFCs) require endothelial protein C receptor (EPCR) for cell cycle progression and angiogenic activity.Angiogenesis · 2025Article
- Bayesian networks for network inference in biology.Journal of the Royal Society, Interface · 2025Review
- Promoting Resiliency to Stress in the Vascular Endothelium.Basic & clinical pharmacology & toxicology · 2025Review
- In silico screening system based on a transcription factors regulatory network only using transcriptomic data.PloS one · 2025Article
- Erk1/2 is not required for endothelial barrier establishment despite its requirement for cAMP-dependent Rac1 activation in heart endothelium.Tissue barriers · 2025Article
- Succinate Regulates Endothelial Mitochondrial Function and Barrier Integrity.Antioxidants (Basel, Switzerland) · 2024Article
- Midkine promotes renal fibrosis by stabilizing C/EBPβ to facilitate endothelial-mesenchymal transition.Communications biology · 2024Article
- Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation.The oncologist · 2024Review
- MEK inhibitors: a promising targeted therapy for cardiovascular disease.Frontiers in cardiovascular medicine · 2024Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 5 institutions in 1 country.
Nicolas RicardYale Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.
Rizaldy P ScottFeinberg Cardiovascular and Renal Research Institute, Division of Nephrology/Hypertension, Feinberg School of Medicine, Northwestern University, Chicago, IL.ORCID 0000-0002-0288-8862
Carmen J BoothDepartment of Comparative Medicine, Yale University School of Medicine, New Haven, CT.
Heino VelazquezDepartment of Medicine, Veterans Affairs Connecticut Healthcare System, Yale University, New Haven, CT.
Nicholas A CilfoneComputational Statistics and Bioinformatics Group, Advanced Artificial Intelligence Research Laboratory, WuXi NextCODE, Cambridge, MA.
Javier L BaylonComputational Statistics and Bioinformatics Group, Advanced Artificial Intelligence Research Laboratory, WuXi NextCODE, Cambridge, MA.
Jeffrey R GulcherCancer Genetics Group, WuXi NextCODE, Cambridge, MA.
Susan E QuagginFeinberg Cardiovascular and Renal Research Institute, Division of Nephrology/Hypertension, Feinberg School of Medicine, Northwestern University, Chicago, IL.ORCID 0000-0002-3706-5727
Thomas W Chittenden *Computational Statistics and Bioinformatics Group, Advanced Artificial Intelligence Research Laboratory, WuXi NextCODE, Cambridge, MA tchittenden@wuxinextcode.com.
Michael Simons *Yale Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT michael.simons@yale.edu.ORCID 0000-0003-0348-7734
Yale University · USIntel (United States) · USNorthwestern University · USBoston Children's Hospital · USCancer Genetics (United States) · US
Funding
Surgery / Physiology CoreP01HL107205 · NHLBI · YALE UNIVERSITY · PI SIMONS, MICHAEL · 2012 to 2022
$18.8MRenal Physiology and Phenotyping CoreP30DK079310 · NIDDK · YALE UNIVERSITY · PI ARONSON, PETER S. · 2008 to 2022
$16.8MEndothelial-to-mesenchyma transition and atherosclerosisR01HL135582 · NHLBI · YALE UNIVERSITY · PI SCHWARTZ, MARTIN A, SIMONS, MICHAEL · 2017 to 2024
$6.6MTherapeutics Development Core (Core B)P30DK114857 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SCHNAPER, H WILLIAM · 2018 to 2022
$5.7MExploiting Tie2 Activation for the Treatment of Vascular DiseasesR01HL124120 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI QUAGGIN, SUSAN E. · 2014 to 2017
$1.5MNHLBI NIH HHS P01 HL107205NHLBI NIH HHS R01 HL124120NHLBI NIH HHS R01 HL135582NIDDK NIH HHS P30 DK079310NIDDK NIH HHS P30 DK114857
Abstract
To define the role of ERK1/2 signaling in the quiescent endothelium, we induced endothelial
Indexed as
AnimalsDeep LearningDisease Models, AnimalEndothelin-1EndotheliumEpithelial-Mesenchymal TransitionHumansHuman Umbilical Vein Endothelial CellsHypertensionMAP Kinase Signaling SystemMiceMice, Inbred C57BLMice, KnockoutMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Nitric Oxide Synthase Type IIIEndothelin-1MAPK1 protein, humanMapk1 protein, mouseMAPK3 protein, humanMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Nitric Oxide Synthase Type IIINOS3 protein, humanNos3 protein, mouseTransforming Growth Factor beta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.